Orphan drug designations are granted to encourage the development of treatments for rare diseases, including rare cancers. Regulatory agencies offer incentives, such as market exclusivity, tax credits, and fee waivers, to companies developing orphan drugs. In the U.S., the Orphan Drug Act provides these incentives, while the EMA has a similar program in the European Union.